APO Research
Talk to an analyst

APO RESEARCH · REPORT

Diagnostic Nuclear Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Diagnostic Nuclear Drug Market Analysis and Forecast 2026-2032

2 January 2026190 pages

Choose your research edition.

Industry ResearchDiagnostic Nuclear Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Diagnostic Nuclear Drug Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Diagnostic Nuclear Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Diagnostic Nuclear Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Diagnostic Nuclear Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Diagnostic Nuclear Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Diagnostic Nuclear Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Diagnostic Nuclear Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Diagnostic Nuclear Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Diagnostic Nuclear Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Diagnostic Nuclear Drug include Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, SIEMENS, Dongcheng and Eli Lilly, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Diagnostic Nuclear Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Diagnostic Nuclear Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Diagnostic Nuclear Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Diagnostic Nuclear Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Diagnostic Nuclear Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Diagnostic Nuclear Drug revenue, projected growth trends, production technology, application and end-user industry.

Diagnostic Nuclear Drug Segment by Company

Bracco Imaging

Cardinal Health

Curium Pharma

GE Healthcare

Jubilant Pharma

Lantheus

SIEMENS

Dongcheng

Eli Lilly

Novartis

China Isotope & Radiation

Diagnostic Nuclear Drug Segment by Type

Tc-99m

F-18

Other

Diagnostic Nuclear Drug Segment by Application

Oncology

Cardiology

Other

Diagnostic Nuclear Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diagnostic Nuclear Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Diagnostic Nuclear Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diagnostic Nuclear Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Diagnostic Nuclear Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Diagnostic Nuclear Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Diagnostic Nuclear Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Diagnostic Nuclear Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Tc-99m Major Player Table 3. F-18 Major Player Table 4. Other Major Player Table 5. Global Diagnostic Nuclear Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Oncology Major Player Table 7. Cardiology Major Player Table 8. Other Major Player Table 9. Diagnostic Nuclear Drug Industry Trends Table 10. Diagnostic Nuclear Drug Industry Drivers Table 11. Diagnostic Nuclear Drug Industry Opportunities and Challenges Table 12. Diagnostic Nuclear Drug Industry Restraints Table 13. Global Diagnostic Nuclear Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Diagnostic Nuclear Drug Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Diagnostic Nuclear Drug Market Share by Region (2021-2026) Table 16. Global Diagnostic Nuclear Drug Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Diagnostic Nuclear Drug Market Share by Region (2027-2032) Table 18. Global Diagnostic Nuclear Drug Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Diagnostic Nuclear Drug Revenue Market Share by Players (2021-2026) Table 20. Global Diagnostic Nuclear Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Diagnostic Nuclear Drug Key Players Headquarters & Area Served Table 22. Global Diagnostic Nuclear Drug Players, Product Type & Application Table 23. Global Diagnostic Nuclear Drug Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Diagnostic Nuclear Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Diagnostic Nuclear Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Diagnostic Nuclear Drug Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Diagnostic Nuclear Drug Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Diagnostic Nuclear Drug Revenue Market Share by Type (2021-2026) Table 30. Global Diagnostic Nuclear Drug Revenue Market Share by Type (2027-2032) Table 31. Global Diagnostic Nuclear Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Diagnostic Nuclear Drug Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Diagnostic Nuclear Drug Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Diagnostic Nuclear Drug Revenue Market Share by Application (2021-2026) Table 35. Global Diagnostic Nuclear Drug Revenue Market Share by Application (2027-2032) Table 36. Bracco Imaging Company Information Table 37. Bracco Imaging Business Overview Table 38. Bracco Imaging Diagnostic Nuclear Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Bracco Imaging Diagnostic Nuclear Drug Product Portfolio Table 40. Bracco Imaging Recent Development Table 41. Cardinal Health Company Information Table 42. Cardinal Health Business Overview Table 43. Cardinal Health Diagnostic Nuclear Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Cardinal Health Diagnostic Nuclear Drug Product Portfolio Table 45. Cardinal Health Recent Development Table 46. Curium Pharma Company Information Table 47. Curium Pharma Business Overview Table 48. Curium Pharma Diagnostic Nuclear Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Curium Pharma Diagnostic Nuclear Drug Product Portfolio Table 50. Curium Pharma Recent Development Table 51. GE Healthcare Company Information Table 52. GE Healthcare Business Overview Table 53. GE Healthcare Diagnostic Nuclear Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. GE Healthcare Diagnostic Nuclear Drug Product Portfolio Table 55. GE Healthcare Recent Development Table 56. Jubilant Pharma Company Information Table 57. Jubilant Pharma Business Overview Table 58. Jubilant Pharma Diagnostic Nuclear Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Jubilant Pharma Diagnostic Nuclear Drug Product Portfolio Table 60. Jubilant Pharma Recent Development Table 61. Lantheus Company Information Table 62. Lantheus Business Overview Table 63. Lantheus Diagnostic Nuclear Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Lantheus Diagnostic Nuclear Drug Product Portfolio Table 65. Lantheus Recent Development Table 66. SIEMENS Company Information Table 67. SIEMENS Business Overview Table 68. SIEMENS Diagnostic Nuclear Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. SIEMENS Diagnostic Nuclear Drug Product Portfolio Table 70. SIEMENS Recent Development Table 71. Dongcheng Company Information Table 72. Dongcheng Business Overview Table 73. Dongcheng Diagnostic Nuclear Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Dongcheng Diagnostic Nuclear Drug Product Portfolio Table 75. Dongcheng Recent Development Table 76. Eli Lilly Company Information Table 77. Eli Lilly Business Overview Table 78. Eli Lilly Diagnostic Nuclear Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Eli Lilly Diagnostic Nuclear Drug Product Portfolio Table 80. Eli Lilly Recent Development Table 81. Novartis Company Information Table 82. Novartis Business Overview Table 83. Novartis Diagnostic Nuclear Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Novartis Diagnostic Nuclear Drug Product Portfolio Table 85. Novartis Recent Development Table 86. China Isotope & Radiation Company Information Table 87. China Isotope & Radiation Business Overview Table 88. China Isotope & Radiation Diagnostic Nuclear Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. China Isotope & Radiation Diagnostic Nuclear Drug Product Portfolio Table 90. China Isotope & Radiation Recent Development Table 91. North America Diagnostic Nuclear Drug Revenue by Type (2021-2026) & (US$ Million) Table 92. North America Diagnostic Nuclear Drug Revenue by Type (2027-2032) & (US$ Million) Table 93. North America Diagnostic Nuclear Drug Revenue by Application (2021-2026) & (US$ Million) Table 94. North America Diagnostic Nuclear Drug Revenue by Application (2027-2032) & (US$ Million) Table 95. North America Diagnostic Nuclear Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 96. North America Diagnostic Nuclear Drug Revenue by Country (2021-2026) & (US$ Million) Table 97. North America Diagnostic Nuclear Drug Revenue by Country (US$ Million) & (2027-2032) Table 98. Europe Diagnostic Nuclear Drug Revenue by Type (2021-2026) & (US$ Million) Table 99. Europe Diagnostic Nuclear Drug Revenue by Type (2027-2032) & (US$ Million) Table 100. Europe Diagnostic Nuclear Drug Revenue by Application (2021-2026) & (US$ Million) Table 101. Europe Diagnostic Nuclear Drug Revenue by Application (2027-2032) & (US$ Million) Table 102. Europe Diagnostic Nuclear Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 103. Europe Diagnostic Nuclear Drug Revenue by Country (2021-2026) & (US$ Million) Table 104. Europe Diagnostic Nuclear Drug Revenue by Country (US$ Million) & (2027-2032) Table 105. China Diagnostic Nuclear Drug Revenue by Type (2021-2026) & (US$ Million) Table 106. China Diagnostic Nuclear Drug Revenue by Type (2027-2032) & (US$ Million) Table 107. China Diagnostic Nuclear Drug Revenue by Application (2021-2026) & (US$ Million) Table 108. China Diagnostic Nuclear Drug Revenue by Application (2027-2032) & (US$ Million) Table 109. Asia Diagnostic Nuclear Drug Revenue by Type (2021-2026) & (US$ Million) Table 110. Asia Diagnostic Nuclear Drug Revenue by Type (2027-2032) & (US$ Million) Table 111. Asia Diagnostic Nuclear Drug Revenue by Application (2021-2026) & (US$ Million) Table 112. Asia Diagnostic Nuclear Drug Revenue by Application (2027-2032) & (US$ Million) Table 113. Asia Diagnostic Nuclear Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 114. Asia Diagnostic Nuclear Drug Revenue by Region (US$ Million) & (2021-2026) Table 115. Asia Diagnostic Nuclear Drug Revenue by Region (US$ Million) & (2027-2032) Table 116. SAMEA Diagnostic Nuclear Drug Revenue by Type (2021-2026) & (US$ Million) Table 117. SAMEA Diagnostic Nuclear Drug Revenue by Type (2027-2032) & (US$ Million) Table 118. SAMEA Diagnostic Nuclear Drug Revenue by Application (2021-2026) & (US$ Million) Table 119. SAMEA Diagnostic Nuclear Drug Revenue by Application (2027-2032) & (US$ Million) Table 120. SAMEA Diagnostic Nuclear Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. SAMEA Diagnostic Nuclear Drug Revenue by Country (2021-2026) & (US$ Million) Table 122. SAMEA Diagnostic Nuclear Drug Revenue by Country (US$ Million) & (2027-2032) Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Diagnostic Nuclear Drug Image Figure 2. Global Diagnostic Nuclear Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Diagnostic Nuclear Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Tc-99m Image Figure 5. F-18 Image Figure 6. Other Image Figure 7. Global Diagnostic Nuclear Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Diagnostic Nuclear Drug Market Size Share 2021 VS 2025 VS 2032 Figure 9. Oncology Image Figure 10. Cardiology Image Figure 11. Other Image Figure 12. Global Diagnostic Nuclear Drug Market Size (US$ Million) & (2021-2032) Figure 13. Global Diagnostic Nuclear Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Diagnostic Nuclear Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Diagnostic Nuclear Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Diagnostic Nuclear Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Diagnostic Nuclear Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Diagnostic Nuclear Drug Revenue Market Share by Type (2021-2032) Figure 20. Global Diagnostic Nuclear Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Diagnostic Nuclear Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Diagnostic Nuclear Drug Revenue Market Share by Application (2021-2032) Figure 23. North America Diagnostic Nuclear Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Diagnostic Nuclear Drug Revenue Share by Type (2021-2032) Figure 25. North America Diagnostic Nuclear Drug Revenue Share by Application (2021-2032) Figure 26. North America Diagnostic Nuclear Drug Revenue Share by Country (2021-2032) Figure 27. United States Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Diagnostic Nuclear Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Diagnostic Nuclear Drug Revenue Share by Type (2021-2032) Figure 32. Europe Diagnostic Nuclear Drug Revenue Share by Application (2021-2032) Figure 33. Europe Diagnostic Nuclear Drug Revenue Share by Country (2021-2032) Figure 34. Germany Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Diagnostic Nuclear Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Diagnostic Nuclear Drug Revenue Share by Type (2021-2032) Figure 44. China Diagnostic Nuclear Drug Revenue Share by Application (2021-2032) Figure 45. Asia Diagnostic Nuclear Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Diagnostic Nuclear Drug Revenue Share by Type (2021-2032) Figure 47. Asia Diagnostic Nuclear Drug Revenue Share by Application (2021-2032) Figure 48. Asia Diagnostic Nuclear Drug Revenue Share by Region (2021-2032) Figure 49. Japan Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Diagnostic Nuclear Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Diagnostic Nuclear Drug Revenue Share by Type (2021-2032) Figure 57. SAMEA Diagnostic Nuclear Drug Revenue Share by Application (2021-2032) Figure 58. SAMEA Diagnostic Nuclear Drug Revenue Share by Country (2021-2032) Figure 59. Brazil Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Diagnostic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Tc-99m
  • F-18
  • Other
Applications
  • Oncology
  • Cardiology
  • Other
Companies covered
  • Bracco Imaging
  • Cardinal Health
  • Curium Pharma
  • GE Healthcare
  • Jubilant Pharma
  • Lantheus
  • SIEMENS
  • Dongcheng
  • Eli Lilly
  • Novartis
  • China Isotope & Radiation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Diagnostic Nuclear Drug Market by Type
  3. 1.2.1 Global Diagnostic Nuclear Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Tc-99m
  5. 1.2.3 F-18
  6. 1.2.4 Other
  7. 1.3 Diagnostic Nuclear Drug Market by Application
  8. 1.3.1 Global Diagnostic Nuclear Drug Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Oncology
  10. 1.3.3 Cardiology
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Diagnostic Nuclear Drug Market Dynamics
  1. 2.1 Diagnostic Nuclear Drug Industry Trends
  2. 2.2 Diagnostic Nuclear Drug Industry Drivers
  3. 2.3 Diagnostic Nuclear Drug Industry Opportunities and Challenges
  4. 2.4 Diagnostic Nuclear Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Diagnostic Nuclear Drug Market Perspective (2021-2032)
  2. 3.2 Global Diagnostic Nuclear Drug Growth Trends by Region
  3. 3.2.1 Global Diagnostic Nuclear Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Diagnostic Nuclear Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Diagnostic Nuclear Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Diagnostic Nuclear Drug Revenue by Players
  2. 4.1.1 Global Diagnostic Nuclear Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Diagnostic Nuclear Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Diagnostic Nuclear Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Diagnostic Nuclear Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Diagnostic Nuclear Drug Key Players Headquarters & Area Served
  7. 4.4 Global Diagnostic Nuclear Drug Players, Product Type & Application
  8. 4.5 Global Diagnostic Nuclear Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Diagnostic Nuclear Drug Market CR5 and HHI
  11. 4.6.3 2025 Diagnostic Nuclear Drug Tier 1, Tier 2, and Tier 3
5 Diagnostic Nuclear Drug Market Size by Type
  1. 5.1 Global Diagnostic Nuclear Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Diagnostic Nuclear Drug Revenue by Type (2021-2032)
  3. 5.3 Global Diagnostic Nuclear Drug Revenue Market Share by Type (2021-2032)
6 Diagnostic Nuclear Drug Market Size by Application
  1. 6.1 Global Diagnostic Nuclear Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Diagnostic Nuclear Drug Revenue by Application (2021-2032)
  3. 6.3 Global Diagnostic Nuclear Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Bracco Imaging
  2. 7.1.1 Bracco Imaging Company Information
  3. 7.1.2 Bracco Imaging Business Overview
  4. 7.1.3 Bracco Imaging Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Bracco Imaging Diagnostic Nuclear Drug Product Portfolio
  6. 7.1.5 Bracco Imaging Recent Developments
  7. 7.2 Cardinal Health
  8. 7.2.1 Cardinal Health Company Information
  9. 7.2.2 Cardinal Health Business Overview
  10. 7.2.3 Cardinal Health Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Cardinal Health Diagnostic Nuclear Drug Product Portfolio
  12. 7.2.5 Cardinal Health Recent Developments
  13. 7.3 Curium Pharma
  14. 7.3.1 Curium Pharma Company Information
  15. 7.3.2 Curium Pharma Business Overview
  16. 7.3.3 Curium Pharma Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Curium Pharma Diagnostic Nuclear Drug Product Portfolio
  18. 7.3.5 Curium Pharma Recent Developments
  19. 7.4 GE Healthcare
  20. 7.4.1 GE Healthcare Company Information
  21. 7.4.2 GE Healthcare Business Overview
  22. 7.4.3 GE Healthcare Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 GE Healthcare Diagnostic Nuclear Drug Product Portfolio
  24. 7.4.5 GE Healthcare Recent Developments
  25. 7.5 Jubilant Pharma
  26. 7.5.1 Jubilant Pharma Company Information
  27. 7.5.2 Jubilant Pharma Business Overview
  28. 7.5.3 Jubilant Pharma Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Jubilant Pharma Diagnostic Nuclear Drug Product Portfolio
  30. 7.5.5 Jubilant Pharma Recent Developments
  31. 7.6 Lantheus
  32. 7.6.1 Lantheus Company Information
  33. 7.6.2 Lantheus Business Overview
  34. 7.6.3 Lantheus Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Lantheus Diagnostic Nuclear Drug Product Portfolio
  36. 7.6.5 Lantheus Recent Developments
  37. 7.7 SIEMENS
  38. 7.7.1 SIEMENS Company Information
  39. 7.7.2 SIEMENS Business Overview
  40. 7.7.3 SIEMENS Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 SIEMENS Diagnostic Nuclear Drug Product Portfolio
  42. 7.7.5 SIEMENS Recent Developments
  43. 7.8 Dongcheng
  44. 7.8.1 Dongcheng Company Information
  45. 7.8.2 Dongcheng Business Overview
  46. 7.8.3 Dongcheng Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Dongcheng Diagnostic Nuclear Drug Product Portfolio
  48. 7.8.5 Dongcheng Recent Developments
  49. 7.9 Eli Lilly
  50. 7.9.1 Eli Lilly Company Information
  51. 7.9.2 Eli Lilly Business Overview
  52. 7.9.3 Eli Lilly Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Eli Lilly Diagnostic Nuclear Drug Product Portfolio
  54. 7.9.5 Eli Lilly Recent Developments
  55. 7.10 Novartis
  56. 7.10.1 Novartis Company Information
  57. 7.10.2 Novartis Business Overview
  58. 7.10.3 Novartis Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Novartis Diagnostic Nuclear Drug Product Portfolio
  60. 7.10.5 Novartis Recent Developments
  61. 7.11 China Isotope & Radiation
  62. 7.11.1 China Isotope & Radiation Company Information
  63. 7.11.2 China Isotope & Radiation Business Overview
  64. 7.11.3 China Isotope & Radiation Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 China Isotope & Radiation Diagnostic Nuclear Drug Product Portfolio
  66. 7.11.5 China Isotope & Radiation Recent Developments
8 North America
  1. 8.1 North America Diagnostic Nuclear Drug Revenue (2021-2032)
  2. 8.2 North America Diagnostic Nuclear Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Diagnostic Nuclear Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Diagnostic Nuclear Drug Revenue by Type (2027-2032)
  5. 8.3 North America Diagnostic Nuclear Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Diagnostic Nuclear Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Diagnostic Nuclear Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Diagnostic Nuclear Drug Revenue by Application (2027-2032)
  9. 8.5 North America Diagnostic Nuclear Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Diagnostic Nuclear Drug Revenue by Country
  11. 8.6.1 North America Diagnostic Nuclear Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Diagnostic Nuclear Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Diagnostic Nuclear Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Diagnostic Nuclear Drug Revenue (2021-2032)
  2. 9.2 Europe Diagnostic Nuclear Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Diagnostic Nuclear Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Diagnostic Nuclear Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Diagnostic Nuclear Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Diagnostic Nuclear Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Diagnostic Nuclear Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Diagnostic Nuclear Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Diagnostic Nuclear Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Diagnostic Nuclear Drug Revenue by Country
  11. 9.6.1 Europe Diagnostic Nuclear Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Diagnostic Nuclear Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Diagnostic Nuclear Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Diagnostic Nuclear Drug Revenue (2021-2032)
  2. 10.2 China Diagnostic Nuclear Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Diagnostic Nuclear Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Diagnostic Nuclear Drug Revenue by Type (2027-2032)
  5. 10.3 China Diagnostic Nuclear Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Diagnostic Nuclear Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Diagnostic Nuclear Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Diagnostic Nuclear Drug Revenue by Application (2027-2032)
  9. 10.5 China Diagnostic Nuclear Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Diagnostic Nuclear Drug Revenue (2021-2032)
  2. 11.2 Asia Diagnostic Nuclear Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Diagnostic Nuclear Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Diagnostic Nuclear Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Diagnostic Nuclear Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Diagnostic Nuclear Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Diagnostic Nuclear Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Diagnostic Nuclear Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Diagnostic Nuclear Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Diagnostic Nuclear Drug Revenue by Country
  11. 11.6.1 Asia Diagnostic Nuclear Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Diagnostic Nuclear Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Diagnostic Nuclear Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Diagnostic Nuclear Drug Revenue (2021-2032)
  2. 12.2 SAMEA Diagnostic Nuclear Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Diagnostic Nuclear Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Diagnostic Nuclear Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Diagnostic Nuclear Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Diagnostic Nuclear Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Diagnostic Nuclear Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Diagnostic Nuclear Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Diagnostic Nuclear Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Diagnostic Nuclear Drug Revenue by Country
  11. 12.6.1 SAMEA Diagnostic Nuclear Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Diagnostic Nuclear Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Diagnostic Nuclear Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst